CD8A and cancer: By fusing a DNA fragment encoding TT to the DNA cancer vaccine, an intense immune response mediated by CD4+ and CD8+ T-cells can be induced against the self-antigen which can, in turn, improve the clinical profile of cancer patients (71–73).